|
July 17, 2008 - APMA Announces HyperMed's New Technology Predicts Healing Potential of Diabetic Ulcers - May Prevent Devastating Diabetic Limb Amputations
read more >
June 16, 2008 - Patrick T. McGloin Appointed Vice President of Marketing of HyperMed, Inc.
read more >
May 19, 2008 - HyperMed, Inc. Receives Additional $4 Million from GBP Capital
read more >
April 21, 2008 - Mark B. Carbeau Appointed Director, Chief Executive Officer and President of HyperMed, Inc. Daniel J. Levangie To Serve as Chairman of the Board of Directors
read more >
January 25, 2008 - HyperMed receives 510K approval to market its second-generation device, OxyVu™-2 for use in determining oxygenation levels in tissue for patients with potential circulatory compromise
read more >
February 28, 2007 - HyperMed, Inc. announces the addition of two directors
to its Board
read more >
February 28, 2007 - HyperMed, Inc. receives $5 million Series A from Greenwich
Biotech Partners
read more >
November 15, 2006 - HyperMed’s OxyVu-1™ receives
510K approval for use to determine oxygenation levels in
tissue for patients with potential circulatory compromise
read
more >
|
